교수 및 연구

리서치하이라이트
리서치하이라이트

Synthetic PPAR Agonist DTMB Alleviates Alzheimer’s Disease Pathology b…

첨부파일
  • 첨부된 파일이 없습니다.
  • 저널명Neurotherapeutics . 2022 Aug 2
    • 담당교수Kyong‑Tai Kim
    • 조회143
    • 작성자최고관리자
    • 2022-08-11

    본문

    ■Abstract

    Abnormal productions of amyloid beta (Aβ) plaque and chronic neuroinflammation are commonly observed in the brain of patients with Alzheimer's disease, and both of which induce neuronal cell death, loss of memory, and cognitive dysfunction. However, many of the drugs targeting the production of Aβ peptides have been unsuccessful in treating Alzheimer's disease. In this study, we identified synthetic novel peroxisome proliferator-activating receptor (PPAR) agonist, DTMB, which can ameliorate the chronic inflammation and Aβ pathological progression of Alzheimer's disease. We discovered that DTMB attenuated the proinflammatory cytokine production of microglia by reducing the protein level of NF-κB. DTMB also improved the learning and memory defects and reduced the amount of Aβ plaque in the brain of 5xFAD mice. This reduction in Aβ pathology was attributed to the changes in gliosis and chronic inflammation level. Additionally, bulk RNA-sequencing showed that genes related to inflammation and cognitive function were changed in the hippocampus and cortex of DTMB-treated mice. Our findings demonstrate that DTMB has the potential to be a novel therapeutic agent for Alzheimer's disease.

     

    ac86c135f5ee1666450ccc22f70a5439_1660197948_6741.jpg